Healthcare / Drug Manufacturers - Specialty & GenericNSE
$834.60
-1.10 (-0.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $17.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.3B
P/E
60.9x
↑EV/EBITDA
N/A
•ROE
9.4%
↑Gross Margin
51.0%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+23.6%
FCF CAGR
—
FCF margin
8.3%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.52B · net income $304.8M · FCF $209.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.52B | $2.52B | $1.78B | $1.53B | $1.33B |
| Net Income | $304.8M | $304.8M | $175.0M | $116.7M | $127.6M |
| EBITDA | $711.8M | $711.8M | $509.4M | $407.0M | $373.5M |
| EPS | — | — | 7.95 | 5.67 | 6.86 |
| Gross Margin | 51.0% | 51.0% | 53.7% | 45.4% | 44.7% |
| Operating Margin | 18.0% | 18.0% | 16.2% | 13.8% | 14.3% |
| Net Margin | 12.1% | 12.1% | 9.9% | 7.6% | 9.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.30 | 0.30 | 0.69 |
| Current Ratio | 1.28 | 1.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $209.1M | $209.1M | $17.5M | $-350.9M | $-488.5M |
| Returns | |||||
| ROE | 9.4% | 9.4% | 6.1% | 4.4% | 7.4% |
| Valuation | |||||
| P/E | 60.88 | 60.88 | 30.47 | 65.06 | 32.47 |
| EV/EBITDA | — | — | 12.16 | 20.60 | 14.28 |
| P/B | — | — | 1.87 | 2.89 | 2.39 |
| Growth & Yield | |||||
| Revenue Growth | 41.8% | 41.8% | 15.8% | 15.0% | — |
| EPS Growth | — | — | 40.1% | -17.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+170.4%
Start / end P/E
n/dx → n/dx
EPS bridge
7.95 → n/d
Residual
+170.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.